Posted On: 06/27/2016 9:59:02 AM
Post# of 72447
"Lots going on" is certainly an understatement. The preclinical drugs for gram negative and fungal infections have the potential to be HUGE multi-billion dollar revenue drugs.
But CTIX already has drugs in human trials for indications with the potential to produce over $10 billion in annual revenue. And that revenue number does NOT include the eye-popping potential of Kevetrin.
And the market currently has CTIX valued at only ~ $180 million... Wow!
But CTIX already has drugs in human trials for indications with the potential to produce over $10 billion in annual revenue. And that revenue number does NOT include the eye-popping potential of Kevetrin.
And the market currently has CTIX valued at only ~ $180 million... Wow!
Quote:
CTIX definitely has lots going on. And, more coming.
Each of the compounds CTIX is developing is a platform compound, with many potential uses. Thus, many compounds, each with many potential commercial applications.
Sooner or later, Mr. Market will get on the CTIX bandwagon. Question for me remains only when. That is why I keep tabs on this gem. - I Need Help
(0)
(0)
